Aficamten - Cytokinetics
Alternative Names: BAY-3723113; CK 3773274; CK-274; MYQORZOLatest Information Update: 09 Jun 2026
At a glance
- Originator Cytokinetics
- Developer Bayer; Corxel Pharmaceuticals; Cytokinetics; Sanofi
- Class Amides; Cardiovascular therapies; Heart failure therapies; Indenes; Oxadiazoles; Pyrazoles; Small molecules
- Mechanism of Action Cardiac myosin inhibitors
-
Orphan Drug Status
Yes - Hypertrophic cardiomyopathy
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Hypertrophic cardiomyopathy